Financial toxicity of medical management of heart failure: JACC Review Topic of the Week Review
| Authors: | Sukumar, S.; Wasfy, J. H.; Januzzi, J. L.; Peppercorn, J.; Chino, F.; Warraich, H. J. |
| Review Title: | Financial toxicity of medical management of heart failure: JACC Review Topic of the Week |
| Abstract: | Optimal medical management of heart failure (HF) improves quality of life, decreases mortality, and decreases hospitalizations. Cost may contribute to suboptimal adherence to HF medications, especially angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2 inhibitors. Patients’ experiences with HF medication cost include financial burden, financial strain, and financial toxicity. Although there has been research studying financial toxicity in patients with some chronic diseases, there are no validated tools for measuring financial toxicity of HF, and very few data on the subjective experiences of patients with HF and financial toxicity. Strategies to decrease HF-associated financial toxicity include making systemic changes to minimize cost sharing, optimizing shared decision-making, implementing policies to lower drug costs, broadening insurance coverage, and using financial navigation services and discount programs. Clinicians may also improve patient financial wellness through various strategies in routine clinical care. Future research is needed to study financial toxicity and associated patient experiences for HF. © 2023 |
| Keywords: | review; comparative study; disease association; quality of life; chronic disease; health care policy; cost effectiveness analysis; drug cost; health care cost; health insurance; prescription; hospitalization; heart failure; insurance; metoprolol; spironolactone; personal experience; medical care; bisoprolol; non insulin dependent diabetes mellitus; cost; health care planning; diabetes mellitus, type 2; health disparity; shared decision making; process optimization; clinician; lisinopril; eplerenone; carvedilol; humans; human; losartan; sacubitril plus valsartan; financial toxicity; financial burden; financial distress; sodium glucose cotransporter 2 inhibitor; financial strain; financial stress; dapagliflozin; empagliflozin; financial crisis; guideline-directed medical therapy; economic well-being; sodium-glucose transporter 2 inhibitors |
| Journal Title: | Journal of the American College of Cardiology |
| Volume: | 81 |
| Issue: | 20 |
| ISSN: | 0735-1097 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-05-23 |
| Start Page: | 2043 |
| End Page: | 2055 |
| Language: | English |
| DOI: | 10.1016/j.jacc.2023.03.402 |
| PUBMED: | 37197848 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- Export Date: 1 June 2023 -- Source: Scopus |
